A detailed history of Federated Hermes, Inc. transactions in Annexon, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 4,924 shares of ANNX stock, worth $25,407. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,924
Previous 2,882 70.85%
Holding current value
$25,407
Previous $14,000 107.14%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.49 - $7.2 $9,168 - $14,702
2,042 Added 70.85%
4,924 $29,000
Q2 2024

Aug 08, 2024

BUY
$4.33 - $6.79 $6,923 - $10,857
1,599 Added 124.63%
2,882 $14,000
Q1 2024

May 14, 2024

BUY
$4.03 - $7.81 $5,170 - $10,020
1,283 New
1,283 $9,000
Q3 2023

Nov 13, 2023

SELL
$2.13 - $3.84 $5.48 Million - $9.88 Million
-2,572,753 Reduced 84.14%
485,047 $1.14 Million
Q3 2022

Nov 14, 2022

BUY
$3.75 - $6.63 $18,150 - $32,089
4,840 Added 0.16%
3,057,800 $18.9 Million
Q2 2022

Aug 15, 2022

BUY
$2.11 - $4.06 $651 - $1,254
309 Added 0.01%
3,052,960 $11.5 Million
Q1 2022

May 13, 2022

BUY
$2.73 - $11.94 $2.8 Million - $12.3 Million
1,027,051 Added 50.7%
3,052,651 $8.33 Million
Q4 2021

Feb 14, 2022

SELL
$11.49 - $22.0 $24,129 - $46,200
-2,100 Reduced 0.1%
2,025,600 $23.3 Million
Q3 2021

Nov 15, 2021

BUY
$16.35 - $23.4 $441,450 - $631,800
27,000 Added 1.35%
2,027,700 $37.7 Million
Q1 2021

May 13, 2021

BUY
$22.0 - $35.01 $12.4 Million - $19.7 Million
563,700 Added 39.23%
2,000,700 $55.7 Million
Q4 2020

Feb 12, 2021

BUY
$20.81 - $30.55 $2.06 Million - $3.02 Million
98,825 Added 7.39%
1,437,000 $36 Million
Q3 2020

Nov 12, 2020

BUY
$17.5 - $30.23 $23.4 Million - $40.5 Million
1,338,175 New
1,338,175 $40.5 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $246M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.